Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters
Amphastar Pharmaceuticals (NASDAQ:AMPH) has announced a significant expansion of its U.S. manufacturing operations at its Rancho Cucamonga, California headquarters. The company plans to quadruple its production capacity over the next 3-5 years, marking its largest domestic infrastructure investment to date.
The expansion includes a new state-of-the-art production plant, enhanced automation, and advanced technologies integration to support critical medication production and pipeline candidates. The initiative will create new jobs across R&D, engineering, manufacturing, and quality operations. Notably, all of Amphastar's finished pharmaceutical products are manufactured in the U.S., reinforcing their commitment to domestic production and supply chain resilience.
Amphastar Pharmaceuticals (NASDAQ:AMPH) ha annunciato una significativa espansione delle sue operazioni di produzione negli Stati Uniti presso la sede di Rancho Cucamonga, California. L'azienda prevede di quadruplicare la capacità produttiva nei prossimi 3-5 anni, rappresentando il più grande investimento infrastrutturale domestico fino ad oggi.
L'espansione prevede una nuova struttura produttiva all'avanguardia, un aumento dell'automazione e l'integrazione di tecnologie avanzate per supportare la produzione di farmaci essenziali e i candidati in pipeline. L'iniziativa creerà nuovi posti di lavoro nei settori R&S, ingegneria, produzione e controllo qualità. È importante sottolineare che tutti i prodotti farmaceutici finiti di Amphastar sono realizzati negli Stati Uniti, rafforzando così l'impegno verso la produzione nazionale e la resilienza della catena di approvvigionamento.
Amphastar Pharmaceuticals (NASDAQ:AMPH) ha anunciado una importante expansión de sus operaciones de fabricación en Estados Unidos en su sede de Rancho Cucamonga, California. La compañía planea cuadruplicar su capacidad de producción en los próximos 3-5 años, marcando su mayor inversión en infraestructura doméstica hasta la fecha.
La expansión incluye una nueva planta de producción de última generación, mayor automatización e integración de tecnologías avanzadas para apoyar la producción de medicamentos críticos y candidatos en desarrollo. Esta iniciativa generará nuevos empleos en I+D, ingeniería, fabricación y operaciones de calidad. Cabe destacar que todos los productos farmacéuticos terminados de Amphastar se fabrican en EE.UU., reforzando su compromiso con la producción nacional y la resiliencia de la cadena de suministro.
Amphastar Pharmaceuticals (NASDAQ:AMPH)는 캘리포니아 란초쿠카몽가 본사에서 미국 내 제조 운영을 대대적으로 확장할 계획을 발표했습니다. 회사는 향후 3-5년 내에 생산 능력을 4배로 확대할 예정이며, 이는 지금까지의 최대 국내 인프라 투자입니다.
확장 계획에는 최첨단 생산 공장 신설, 자동화 강화, 첨단 기술 통합이 포함되어 있으며, 이는 핵심 의약품 생산과 개발 중인 후보 물질 지원을 위한 것입니다. 이번 프로젝트는 연구개발, 엔지니어링, 제조 및 품질 관리 분야에서 새로운 일자리를 창출할 것입니다. 특히 Amphastar의 모든 완제품 의약품은 미국 내에서 제조되어 국내 생산과 공급망 회복력에 대한 의지를 강화합니다.
Amphastar Pharmaceuticals (NASDAQ:AMPH) a annoncé une importante expansion de ses opérations de fabrication aux États-Unis, dans son siège de Rancho Cucamonga, Californie. L'entreprise prévoit de quadrupler sa capacité de production au cours des 3 à 5 prochaines années, marquant son plus grand investissement dans les infrastructures nationales à ce jour.
Cette expansion comprend une nouvelle usine de production ultramoderne, une automatisation renforcée et l'intégration de technologies avancées pour soutenir la production de médicaments essentiels et les candidats en développement. Cette initiative créera de nouveaux emplois dans les domaines de la R&D, de l'ingénierie, de la fabrication et du contrôle qualité. Il est à noter que tous les produits pharmaceutiques finis d'Amphastar sont fabriqués aux États-Unis, renforçant ainsi leur engagement envers la production nationale et la résilience de la chaîne d'approvisionnement.
Amphastar Pharmaceuticals (NASDAQ:AMPH) hat eine bedeutende Erweiterung seiner US-amerikanischen Produktionsstätten am Hauptsitz in Rancho Cucamonga, Kalifornien, angekündigt. Das Unternehmen plant, seine Produktionskapazität in den nächsten 3-5 Jahren auf das Vierfache zu erhöhen, was die bisher größte Investition in die heimische Infrastruktur darstellt.
Die Erweiterung umfasst eine neue hochmoderne Produktionsanlage, verbesserte Automatisierung und die Integration fortschrittlicher Technologien zur Unterstützung der Herstellung wichtiger Medikamente und Pipeline-Kandidaten. Das Projekt wird neue Arbeitsplätze in den Bereichen Forschung & Entwicklung, Ingenieurwesen, Produktion und Qualitätskontrolle schaffen. Bemerkenswert ist, dass alle fertigen pharmazeutischen Produkte von Amphastar in den USA hergestellt werden, was das Engagement für die heimische Produktion und die Widerstandsfähigkeit der Lieferkette unterstreicht.
- Plans to quadruple domestic production capacity over next 3-5 years
- Investment in new state-of-the-art production facility and advanced technologies
- Creation of new jobs across multiple departments
- Strengthening of domestic supply chain resilience
- All finished pharmaceutical products manufactured in the U.S.
- Significant capital expenditure required for expansion
- Extended 3-5 year timeline for completion
- Potential execution risks in scaling operations
Insights
Amphastar's quadrupling of US production capacity strengthens supply chain resilience while potentially boosting margins and competitive positioning.
This manufacturing expansion represents a significant strategic pivot for Amphastar, positioning the company to capitalize on growing demand for domestic pharmaceutical production. The quadrupling of capacity at their Rancho Cucamonga headquarters over 3-5 years isn't just about scale—it's about vertical integration and supply chain resilience.
The investment in a new state-of-the-art production plant with expanded automation will likely yield substantial operational efficiencies and margin improvements. Pharmaceutical manufacturing automation typically reduces labor costs by 25-40% while improving quality consistency—critical for injectable and inhalation products where precision is paramount.
This expansion aligns perfectly with both market and regulatory trends. Post-pandemic, healthcare systems and regulators have prioritized domestic manufacturing of essential medicines to reduce dependency on international supply chains. By doubling down on its "Made in USA" strategy for all finished products, Amphastar is positioning itself advantageously for potential preferential treatment in government contracts and healthcare system purchasing decisions.
The timing is particularly strategic as it coincides with Amphastar's development of new pipeline candidates. Having expanded in-house manufacturing capabilities can accelerate commercialization timelines for proprietary products, where margins are typically 2-3x higher than for generics. This infrastructure investment suggests management's confidence in their R&D pipeline and long-term growth trajectory.
The planned manufacturing expansion represents a counter-cyclical move in the pharmaceutical landscape where outsourcing to CDMOs has been the prevailing trend. By substantially increasing in-house capabilities, Amphastar is making a calculated bet that vertical integration will provide competitive advantages in their specialized product categories.
This investment carries strategic significance beyond mere capacity expansion. Amphastar specializes in technically challenging injectable, inhalation, and intranasal products—areas where manufacturing complexity creates natural barriers to entry. By quadrupling capacity and implementing advanced technologies, they're effectively widening the moat around their technical expertise in difficult-to-manufacture formulations.
The focus on domestic manufacturing aligns with bipartisan policy initiatives to reduce U.S. dependence on foreign pharmaceutical supply chains. This positioning could potentially give Amphastar preferential access to certain government contracts and institutional purchasing agreements that prioritize domestic manufacturers.
Notably, the mention of supporting production for "new pipeline candidates" suggests this expansion isn't just about scaling existing products but enabling growth through innovation. For a company like Amphastar, which balances generic and proprietary products, expanding manufacturing capabilities could accelerate commercialization timelines for higher-margin proprietary drugs while maintaining cost competitiveness in generics.
This multi-year expansion timeline indicates a long-term strategic vision and confidence in sustained demand for their product categories, particularly as healthcare systems increasingly prioritize supply chain security for essential medications.
RANCHO CUCAMONGA, CA / ACCESS Newswire / July 14, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a bio-pharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, has announced a multi-year expansion of its U.S. manufacturing operations at its headquarters in Rancho Cucamonga, California. The company plans to quadruple its production capacity at this location over the next three to five years, reinforcing its commitment to domestic pharmaceutical manufacturing and strengthening supply chain resilience.
This strategic initiative represents the most substantial investment in domestic infrastructure in the company's history. It will feature a new state-of-the-art production plant, expanded automation, and the integration of advanced technologies to support the development and manufacture of critical medications, including supporting the production of new pipeline candidates. Once completed, the company expects to create new jobs in research and development, engineering, manufacturing, and quality operations.
"Expanding our domestic manufacturing footprint is not only a strategic milestone for Amphastar but a reaffirmation of our commitment to producing essential medicines right here in the United States," said Dr. Jack Zhang, Amphastar's President and CEO. "All of our finished pharmaceutical products are proudly manufactured in the U.S., and this long-term investment strengthens the commitment, enhancing our ability to deliver greater flexibility, agility, and quality to the healthcare providers and patients who depend on our products every day."
Amphastar will continue working in close partnership with all levels of government leadership to ensure sustainable growth, workforce development, and alignment with economic and public health priorities.
Company Information
Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.
Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVYTM, Amphadase®, and Cortrosyn®, are the property of Amphastar.
Forward Looking Statements
All statements in this press release referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding expansion of our headquarters, including quadrupling our production capacity and manufacturing capabilities, the resilience of our supply chain, our ability to expand our automation capabilities and integrate advanced technologies, our ability to create new jobs in the future, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 3, 2025, in our Quarterly Report on Form 10-Q for the quarter ending March 31, 2025, filed with the SEC on May 8, 2025, and our other filings or reports that we may file with the SEC. In particular, there can be no guarantee that our sales strategies will be successful, or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.
Contact Information:
Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416
SOURCE: Amphastar Pharmaceuticals, Inc.
View the original press release on ACCESS Newswire
FAQ
What is Amphastar Pharmaceuticals' (AMPH) manufacturing expansion plan for 2025?
How will AMPH's manufacturing expansion affect employment?
Where does Amphastar manufacture its pharmaceutical products?
What types of products does Amphastar Pharmaceuticals manufacture?
What is the timeline for Amphastar's manufacturing expansion project?
